Ampio Pharmaceuticals, Inc. (AMPE)
USD 0.0
(-97.12%)
USD 0.0
(-97.12%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.37 Million USD | 32.07% |
| 2022 | 1.79 Million USD | -84.41% |
| 2021 | 11.54 Million USD | 115.08% |
| 2020 | 5.36 Million USD | -29.0% |
| 2019 | 7.55 Million USD | -14.06% |
| 2018 | 8.79 Million USD | -82.23% |
| 2017 | 49.49 Million USD | 610.93% |
| 2016 | 6.96 Million USD | -44.27% |
| 2015 | 12.49 Million USD | 159.71% |
| 2014 | 4.8 Million USD | 71.54% |
| 2013 | 2.8 Million USD | 39.0% |
| 2012 | 2.01 Million USD | 17.09% |
| 2011 | 1.72 Million USD | -63.7% |
| 2010 | 4.74 Million USD | 4617.84% |
| 2009 | 100.59 Thousand USD | 30.98% |
| 2008 | 76.8 Thousand USD | 75.62% |
| 2007 | 43.73 Thousand USD | 331.19% |
| 2006 | 10.14 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 2.85 Million USD | 58.81% |
| 2023 Q4 | 2.37 Million USD | 4.62% |
| 2023 Q3 | 2.27 Million USD | -12.28% |
| 2023 Q2 | 2.58 Million USD | -9.38% |
| 2023 FY | 2.37 Million USD | 32.07% |
| 2022 Q4 | 1.79 Million USD | -63.94% |
| 2022 FY | 1.79 Million USD | -84.41% |
| 2022 Q3 | 4.98 Million USD | -29.91% |
| 2022 Q2 | 7.11 Million USD | -32.42% |
| 2022 Q1 | 10.53 Million USD | -8.73% |
| 2021 Q4 | 11.54 Million USD | 121.98% |
| 2021 FY | 11.54 Million USD | 115.08% |
| 2021 Q1 | 4.94 Million USD | -7.77% |
| 2021 Q2 | 6.34 Million USD | 28.27% |
| 2021 Q3 | 5.19 Million USD | -18.1% |
| 2020 Q2 | 5.51 Million USD | -19.49% |
| 2020 Q1 | 6.85 Million USD | -9.31% |
| 2020 Q3 | 4.81 Million USD | -12.67% |
| 2020 Q4 | 5.36 Million USD | 11.35% |
| 2020 FY | 5.36 Million USD | -29.0% |
| 2019 FY | 7.55 Million USD | -14.06% |
| 2019 Q3 | 11.82 Million USD | 20.94% |
| 2019 Q2 | 9.77 Million USD | -25.13% |
| 2019 Q1 | 13.06 Million USD | 48.52% |
| 2019 Q4 | 7.55 Million USD | -36.09% |
| 2018 Q4 | 8.79 Million USD | -34.06% |
| 2018 Q1 | 23.52 Million USD | -52.48% |
| 2018 Q2 | 15.43 Million USD | -34.36% |
| 2018 Q3 | 13.33 Million USD | -13.62% |
| 2018 FY | 8.79 Million USD | -82.23% |
| 2017 Q2 | 9.33 Million USD | 60.38% |
| 2017 FY | 49.49 Million USD | 610.93% |
| 2017 Q4 | 49.49 Million USD | 416.26% |
| 2017 Q3 | 9.58 Million USD | 2.73% |
| 2017 Q1 | 5.81 Million USD | -16.42% |
| 2016 Q3 | 7.05 Million USD | 118.83% |
| 2016 Q2 | 3.22 Million USD | -18.06% |
| 2016 Q4 | 6.96 Million USD | -1.27% |
| 2016 FY | 6.96 Million USD | -44.27% |
| 2016 Q1 | 3.93 Million USD | -68.52% |
| 2015 Q2 | 4.6 Million USD | 39.37% |
| 2015 FY | 12.49 Million USD | 159.71% |
| 2015 Q1 | 3.3 Million USD | -31.26% |
| 2015 Q4 | 12.49 Million USD | 17.7% |
| 2015 Q3 | 10.61 Million USD | 130.31% |
| 2014 Q2 | 5.07 Million USD | -5.93% |
| 2014 Q3 | 4.27 Million USD | -15.8% |
| 2014 Q4 | 4.8 Million USD | 12.64% |
| 2014 FY | 4.8 Million USD | 71.54% |
| 2014 Q1 | 5.39 Million USD | 92.28% |
| 2013 Q3 | 2.42 Million USD | -12.86% |
| 2013 Q2 | 2.78 Million USD | 33.28% |
| 2013 Q1 | 2.09 Million USD | 3.68% |
| 2013 FY | 2.8 Million USD | 39.0% |
| 2013 Q4 | 2.8 Million USD | 15.44% |
| 2012 Q2 | 1.5 Million USD | 12.97% |
| 2012 Q4 | 2.01 Million USD | 19.29% |
| 2012 Q3 | 1.69 Million USD | 12.62% |
| 2012 Q1 | 1.32 Million USD | -22.85% |
| 2012 FY | 2.01 Million USD | 17.09% |
| 2011 Q4 | 1.72 Million USD | -19.32% |
| 2011 Q3 | 2.13 Million USD | -10.21% |
| 2011 Q2 | 2.37 Million USD | 18.2% |
| 2011 Q1 | 2.01 Million USD | -57.6% |
| 2011 FY | 1.72 Million USD | -63.7% |
| 2010 Q3 | 1.62 Million USD | 69.0% |
| 2010 FY | 4.74 Million USD | 4617.84% |
| 2010 Q2 | 961.18 Thousand USD | 76.87% |
| 2010 Q1 | 543.43 Thousand USD | 440.22% |
| 2010 Q4 | 4.74 Million USD | 192.17% |
| 2009 Q4 | 100.59 Thousand USD | 6.46% |
| 2009 Q3 | 94.49 Thousand USD | 4.53% |
| 2009 Q2 | 90.39 Thousand USD | 3.88% |
| 2009 FY | 100.59 Thousand USD | 30.98% |
| 2009 Q1 | 87.02 Thousand USD | 13.31% |
| 2008 Q4 | 76.8 Thousand USD | 10.15% |
| 2008 Q2 | 66.5 Thousand USD | 11.58% |
| 2008 Q3 | 69.72 Thousand USD | 4.83% |
| 2008 FY | 76.8 Thousand USD | 75.62% |
| 2008 Q1 | 59.6 Thousand USD | 36.31% |
| 2007 Q4 | 43.73 Thousand USD | 2.43% |
| 2007 Q3 | 42.69 Thousand USD | 0.0% |
| 2007 FY | 43.73 Thousand USD | 331.19% |
| 2006 Q4 | 10.14 Thousand USD | 0.0% |
| 2006 FY | 10.14 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 9.14 Million USD | 74.024% |
| Armata Pharmaceuticals, Inc. | 142.02 Million USD | 98.327% |
| Actinium Pharmaceuticals, Inc. | 45.06 Million USD | 94.728% |
| Azitra, Inc. | 2.2 Million USD | -7.885% |
| Can-Fite BioPharma Ltd. | 3.74 Million USD | 36.572% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | 63.675% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | 86.984% |
| CEL-SCI Corporation | 17.31 Million USD | 86.276% |
| iBio, Inc. | 7.41 Million USD | 67.935% |
| Lineage Cell Therapeutics, Inc. | 38.99 Million USD | 93.907% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | 66.485% |
| Matinas BioPharma Holdings, Inc. | 46.33 Million USD | 94.872% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 81.015% |
| NovaBay Pharmaceuticals, Inc. | 5.72 Million USD | 58.462% |
| NanoViricides, Inc. | 1.35 Million USD | -74.863% |
| Oragenics, Inc. | 1.79 Million USD | -32.134% |
| BiomX Inc. | 55.07 Million USD | 95.686% |
| BiomX Inc. | 55.07 Million USD | 95.686% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | 95.329% |
| Palatin Technologies, Inc. | 10.85 Million USD | 78.109% |
| Scorpius Holdings, Inc. | 22.74 Million USD | 89.553% |
| Theriva Biologics, Inc. | 20.51 Million USD | 88.418% |